Operating Margin % is calculated as Operating Income divided by its Revenue. Intercept Pharmaceuticals's Operating Income for the
three
months ended in Mar. 2023 was $-31.6 Mil. Intercept Pharmaceuticals's Revenue for the
three
months ended in Mar. 2023 was $68.0 Mil. Therefore, Intercept Pharmaceuticals's Operating Margin % for the quarter that ended in Mar. 2023 was -46.55%.
Good Sign:
Intercept Pharmaceuticals Inc operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Intercept Pharmaceuticals's Operating Margin % or its related term are showing as below:
ICPT'
s Operating Margin % Range Over the Past 10 Years
Min: -8237.1 Med: -207.53 Max: -23.88
Current: -24.83
ICPT's Operating Margin % is ranked better than 68.49% of 1022
companies
in the Biotechnology industry
Industry Median: -197.83
vs ICPT: -24.83
Intercept Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 37.40% per year.
Intercept Pharmaceuticals's Operating Income for the
three
months ended in Mar. 2023 was $-31.6 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2023 was $-73.1 Mil.
Intercept Pharmaceuticals Operating Margin % Historical Data
The historical data trend for Intercept Pharmaceuticals's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Intercept Pharmaceuticals Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Operating Margin %
-158.78
-123.98
-93.14
-38.62
-23.88
Intercept Pharmaceuticals Quarterly Data
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Operating Margin %
-44.68
-18.62
-13.07
-23.29
-46.55
Competitive Comparison
For the Biotechnology subindustry, Intercept Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intercept Pharmaceuticals Operating Margin % Distribution
For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Intercept Pharmaceuticals's Operating Margin % falls in comparison to its industry or sector. The grey bar indicates the Operating Margin %'s extreme value range as defined by GuruFocus.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Intercept Pharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But NokiaÂ’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Intercept Pharmaceuticals Operating Margin % Related Terms
Thank you for viewing the detailed overview of Intercept Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Intercept Pharmaceuticals (NAS:ICPT) Business Description
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Create New Portfolio
Portfolio Contest
Personalize
Premium Gurus 
0.51(5.23%) Volume: 1,489,063 4:00PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
ICPT has been successfully added to your 
